During National Lyme Disease Awareness Month, arm yourself with ZEUS Borrelia MTTT

ZEUS supports National Lyme Disease Awareness Month

May is Lyme Disease Awareness Month, an important reminder for us all to be proactive to protect ourselves against Lyme disease, know the symptoms and if suspected, get tested and treated early. Are you still following STTT and using immunoblots?  Patients deserve accurate, reliable and objective tests.  ZEUS Borrelia MTTT nearly doubles your lab's detection of early Lyme disease, allowing patients to get the treatment they need.  If you are ready to make the change to a more accurate Lyme disease testing algorithm, let us help you make the switch to ZEUS Scientific's Borrelia Modified Two-Tiered Testing (MTTT) algorithm and see what you have been missing:

Fact: Lyme disease is the largest vector borne disease in the USA. CDC estimates that approximately 476,000 Americans are diagnosed and treated for Lyme disease each year.

Fact: In a 2022 Journal of Clinical Microbiology publication*, ZEUS Borrelia MTTT was shown to detect nearly double the cases of early Lyme disease compared to the Standard Two-Tiered Testing (STTT) algorithm.

Fact: Early diagnosis and proper antibiotic treatment of Lyme disease is important and can help prevent late Lyme disease**

The ZEUS Borrelia MTTT algorithm consolidates both testing tiers with one ELISA method that follows ZEUS’s universal protocol. See what you have been missing by using the ZEUS Borrelia MTTT algorithm and replace outdated immunoblots with a 2nd tier ELISA.

 

---

Trust the experts in Lyme disease testing.
Test with Confidence. Test with ZEUS.

---

 

Simplify and improve your Lyme disease testing. Learn more at zeuslyme.com or email us at sales@zeusscientific.com.

 

Best,

The ZEUS Scientific Team

 

 

_{* pubmed.ncbi.nlm.nih.gov/35418241/  Both ZEUS Borrelia MTTT algorithms are significantly more sensitive in patients with acute EM (erythema migrans) compared with STTT.  The difference is most pronounced with MTTT-2, using this approach, the number of EM cases detected nearly doubled in comparison with STTT (74% versus 41%)”. Of the 61 patients tested with confirmed EM, ZEUS MTTT-2 detected 45 while STTT detected 25 (74% vs 41%)}

_{**https://www.cdc.gov/lyme/treatment/index.html}

Back Share